Form 4: Column Group Boosts Surrozen Stake with $640K Share Purchases

The Column Group III GP, LP and affiliated entities acquired over 32,500 shares of Surrozen, Inc. common stock across multiple transactions in mid-January 2026.

Summary

• The Column Group III GP, LP, a 10% owner and director-affiliated entity of Surrozen, Inc. (SRZN), reported multiple acquisitions of common stock.
• On January 15, 2026, The Column Group III, LP acquired 5,590 shares at $19.889 per share, and The Column Group III-A, LP acquired 6,303 shares at $19.889 per share.
• On January 16, 2026, The Column Group III, LP acquired 1,204 shares at $20.00 per share, and The Column Group III-A, LP acquired 1,358 shares at $20.00 per share.
• On January 20, 2026, The Column Group III, LP acquired 8,484 shares at $19.5999 per share, and The Column Group III-A, LP acquired 9,568 shares at $19.5999 per share.
• In total, 32,507 shares of common stock were acquired across these transactions, amounting to approximately $641,589.
• Following these transactions, The Column Group III, LP beneficially owns 900,292 shares, The Column Group III-A, LP beneficially owns 1,016,658 shares, and The Column Group Opportunity III, LP beneficially owns 344,827 shares.
• Peter Svennilson and Tim Kutzkey, a member of Surrozen's board of directors, are managing partners of the general partners of these entities and may be deemed to share voting and investment power, disclaiming beneficial ownership except for their pecuniary interest.

Sentiment

Score: 8

Explanation: The sentiment is strongly positive due to significant insider buying by a 10% owner and director-affiliated entities, signaling strong internal confidence in the company's value and future performance.

Positives

• Significant insider buying by a 10% owner and director-affiliated entity, indicating confidence in the company's future prospects.
• The acquisitions represent a substantial investment of approximately $641,589 in Surrozen common stock.
• Increased beneficial ownership by key institutional investors and individuals associated with the board of directors.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company's management, focusing solely on past insider transactions.

Industry Context

Insider buying in a biotechnology company like Surrozen, Inc. can signal internal confidence in ongoing research, development pipelines, or upcoming milestones, which is a common driver of investor sentiment in the sector.

Related Party Transactions

• The reported transactions involve entities (The Column Group III GP, LP and its affiliates) that are 10% owners and have a director (Tim Kutzkey) associated with their managing partners, making these related-party transactions.

Stakeholder Impact

• Shareholders may view the insider buying as a positive indicator, potentially increasing confidence in the stock.
• The increased stake by a significant institutional investor could be seen as a vote of confidence in the company's strategic direction and long-term value.

Key Dates

Recommendation

The substantial insider buying by a 10% owner and director-affiliated entities is a strong positive signal. Such actions typically indicate that those with deep knowledge of the company believe the stock is undervalued or poised for future growth, making it an attractive buying opportunity for investors.

Keywords

Surrozen, SRZN, Column Group, insider buying, beneficial ownership, equity acquisition, Form 4, biotechnology, pharmaceutical